TABLE II.
Antibodies against thyroid hormones detected in the study groups
| Antibody detected | Study groups | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||
| Patients with hematologic malignancies | Control subjects (n=104) | ||||||||||||||
|
| |||||||||||||||
| MM (n=22) | CML (n=8) | CLL (n=4) | NHL (n=36) | PV (n=12) | Overall (n=82) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
| (n) | (%) | (n) | (%) | (n) | (%) | (n) | (%) | (n) | (%) | (n) | (%) | (n) | (%) | ||
| Any antibody | 3 | 14 | 2 | 25 | 1 | 25 | 5 | 14 | 0 | 0 | 11 | 13 | 1 | 1 | |
| Antibody subtype | |||||||||||||||
| T3-IgM | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | |
| T3-IgG | 1 | 4 | 1 | 12 | 1 | 25 | 3 | 8 | 0 | 0 | 6 | 7 | 1 | 0 | |
| T4-IgM | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |
| T4-IgG | 0 | 0 | 1 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |
| T4-IgM and T4-IgG | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | |
| All four antibodies | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | |
MM = multiple myeloma; CML = chronic myeloid leukemia; CLL = chronic lymphatic leukemia; NHL = non Hodgkin lymphoma; PV = polycythemia vera; Ig = immunoglobulin.